if they can be used in 30m surgeries which is just over 1 in 2...

First 14 Last

Share
Profile

Follow
EDDYDudes

207 Posts.

59

17/03/24

13:12

Post #: 72927242
Share
Originally posted by Montytheman: ↑

Thanks heaps team. O.K with Q1 closing soon. My predictions on some basic modelling and salient related information are as below:

Q1 Revenue - $8.4M
GM% - 79%. New suppliers, new sales team, new target market is creating economies of scale, economies of learning, cost compression, and improved purchasing power
Negative Operating Cash Flow - $2.2M
BEP 3rd or 4th 1/4 2024
The GPO is the game changer - only our second full quarter it has been in full effect, with 1600 hospitals and 43,000 alternative sites! Reports are the GPO is in very high demand of XPERIENCE & BlastX
The DME is in an expansion, with a second site underway to manage the demand of the DME orders!
Further Publications of Clinical Research in 2024 with enhance the recognition in the medical community
New sales team in critical states to increase quality of sales and revenue. Already selling in 40 states of America and increasing
TBH (Acne) has gone National and International in global stores. We have secured a new commercial arrangement (Royalties) with TBH as per the recent presentation by IV. We have diversified income streams that are building phenomenal CAGR..
Direct wound care sales were up 411% yoy due to the first full year of the DME!!!
The extended Walker family have committed to the long-term future of NXS (Largest Shareholder)
We save lives and improve patient outcomes; and reduce re-admissions. We have a solution to the global problem of Biofilm in a growing TAM of $12.5B! The USA alone does 50M surgeries PA which will benefit from our XBIO technology; and has already done so over the last four years..
The re-rate will be in 2024. The share price will look after itself. It will trade well over the IPO of a $1 once Cash Flow positive. As of the 1st of Jan 2024, we had $9.24 M in cash with Zero debt. For a growth company to have Zero debt - very very rare!!!!!...
IV is a Global Leader, a Global Influencer in this market, with a Global Team who is based directly in the USA. Don't underestimate this positive change agent. It hasn't even been 9 months under the new Leadership Team.
The Investor Enquires email is great, NXS will get back to you very quick with any concerns or ideas.

For Long Term Investors - support the product and awareness; and grab a cigar in 2024/2025.

Cheers
Monty

Expand

if they can be used in 30m surgeries which is just over 1 in 2 surgeries, then we are looking at 3.5b in sales. With a forecasted 20% EBITA margin we are looking towards a $10B company. I think that re-rate will kick it off, but another 4-5 years, then it might over perform to $35/share which would be insane.
NXS Price at posting: 38.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

3 Great analysis

Reply